DESCRIPTION:

List of positional candidate genes after correcting for multiple testing and controlling the false discovery rate from genome wide association studies (GWAS) retrieved from the NHGRI-EBI Catalog of published genome-wide association studies (http://www.ebi.ac.uk/gwas/). The disease/trait examined in this study, as reported by the authors, was Creatine kinase in statin users. The EFO term response to statin, creatine kinase measurement was annotated to this set after curation by NHGRI-EBI. Intergenic SNPS were mapped to both the upstream and downstream gene. P-value uploaded. This gene set was generated using gwas2gs v. 0.1.8 and the GWAS Catalog v. 1.0.1.

LABEL:

GWAS: response to statin, creatine kinase measurement

SCORE TYPE:

P-Value

DATE ADDED:

2017-05-02

DATE UPDATED:

2024-04-25

SPECIES:

AUTHORS:

MP Dubé, R Zetler, A Barhdadi, AM Brown, I Mongrain, V Normand, N Laplante, G Asselin, YF Zada, S Provost, J Bergeron, S Kouz, R Dufour, A Diaz, S de Denus, J Turgeon, E Rhéaume, MS Phillips, JC Tardif

TITLE:

CKM and LILRB5 are associated with serum levels of creatine kinase.

JOURNAL:

Circulation. Cardiovascular genetics Dec 2014, Vol 7, pp. 880-6

ABSTRACT:

Statins (HMG-CoA reductase inhibitors) are the most prescribed class of lipid-lowering drugs for the treatment and prevention of cardiovascular disease. Creatine kinase (CK) is a commonly used biomarker to assist in the diagnosis of statin-induced myotoxicity but the normal range of CK concentrations is wide, which limits its use as a diagnostic biomarker. PUBMED: 25214527
Find other GeneSets from this publication